董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brian Stuglik | 男 | Director,Chief Executive Officer | 62 | 381.53万美元 | 未持股 | 2022-04-01 |
| Eric Rowinsky | 男 | Director | 65 | 22.26万美元 | 未持股 | 2022-04-01 |
| Paul Bunn | 男 | Director | 76 | 25.29万美元 | 未持股 | 2022-04-01 |
| John Johnson | -- | Director | 64 | 未披露 | 未持股 | 2022-04-01 |
| Michelle Robertson | 女 | Director | 55 | 14.44万美元 | 未持股 | 2022-04-01 |
| Lesley Solomon | 女 | Director | 50 | 25.55万美元 | 未持股 | 2022-04-01 |
| John H. Johnson | 男 | Director | 64 | 13.14万美元 | 未持股 | 2022-04-01 |
| Michael G. Kauffman | 男 | Director | 58 | 15.88万美元 | 未持股 | 2022-04-01 |
| Timothy Barberich | 男 | Director | 74 | 14.18万美元 | 未持股 | 2022-04-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brian Stuglik | 男 | Director,Chief Executive Officer | 62 | 381.53万美元 | 未持股 | 2022-04-01 |
| Robert Gagnon | 男 | Chief Business and Financial Officer | 47 | 169.69万美元 | 未持股 | 2022-04-01 |
| Daniel Paterson | 男 | President, Chief Operating Officer | 60 | 183.37万美元 | 未持股 | 2022-04-01 |
董事简历
中英对照 | 中文 | 英文- Brian Stuglik
-
Brian Stuglik是二类董事，自2019年7月起担任首席执行官，自2017年9月起担任董事会成员。Stuglik先生于2016年1月创立Proventus Health Solutions，在美国和国际药品开发，产品战略和商业化方面拥有超过三十年的经验。在创立Proventus Health Solutions之前，Stuglik先生于2009年至2015年12月担任礼来公司肿瘤部门的Vice President兼首席营销官。Stuglik先生在普渡大学（Purdue University）获得药学理学学士学位，并持有美国临床肿瘤学学会、美国癌症研究协会和国际肺癌研究协会的会员资格。
Brian Stuglik, is a Class II director who has served as our Chief Executive Officer since July 2019 and as a member of our Board of Directors since September 2017. Mr. Stuglik founded Proventus Health Solutions, a consulting company for pharmaceutical and biotechnology companies, in January 2016 and has over three decades of experience in U.S. and international pharmaceutical development, product strategy, and commercialization. Prior to founding Proventus Health Solutions, Mr. Stuglik served as the Vice President and Chief Marketing Officer for the oncology division of Eli Lilly and Company, from 2009 to December 2015. Mr. Stuglik currently serves on the board of directors of publicly traded Oncopeptides AB ONCO and Puma Biotechnology, Inc. (PBYI). Mr. Stuglik received a Bachelor of Science in Pharmacy from Purdue University and holds memberships in the American Society of Clinical Oncology, the American Association of Cancer Research, and the International Association for the Study of Lung Cancer. - Brian Stuglik是二类董事，自2019年7月起担任首席执行官，自2017年9月起担任董事会成员。Stuglik先生于2016年1月创立Proventus Health Solutions，在美国和国际药品开发，产品战略和商业化方面拥有超过三十年的经验。在创立Proventus Health Solutions之前，Stuglik先生于2009年至2015年12月担任礼来公司肿瘤部门的Vice President兼首席营销官。Stuglik先生在普渡大学（Purdue University）获得药学理学学士学位，并持有美国临床肿瘤学学会、美国癌症研究协会和国际肺癌研究协会的会员资格。
- Brian Stuglik, is a Class II director who has served as our Chief Executive Officer since July 2019 and as a member of our Board of Directors since September 2017. Mr. Stuglik founded Proventus Health Solutions, a consulting company for pharmaceutical and biotechnology companies, in January 2016 and has over three decades of experience in U.S. and international pharmaceutical development, product strategy, and commercialization. Prior to founding Proventus Health Solutions, Mr. Stuglik served as the Vice President and Chief Marketing Officer for the oncology division of Eli Lilly and Company, from 2009 to December 2015. Mr. Stuglik currently serves on the board of directors of publicly traded Oncopeptides AB ONCO and Puma Biotechnology, Inc. (PBYI). Mr. Stuglik received a Bachelor of Science in Pharmacy from Purdue University and holds memberships in the American Society of Clinical Oncology, the American Association of Cancer Research, and the International Association for the Study of Lung Cancer.
- Eric Rowinsky
-
Eric Rowinsky是一级董事，自2017年5月以来一直担任我们的董事会成员。Rowinsky博士自2016年6月起担任Rgenix，Inc.的执行董事兼总裁。他还自2016年6月起担任ClearPath Development Co.的首席科学官。在此之前，罗温斯基博士于2011年2月至2016年1月担任StemlineTherapeutics，Inc.研究与开发主管，首席医疗官兼执行Vice President。2010年，Rowinsky博士共同创立Primrose Therapeutics，并成为其首席执行官，直到2011年被收购。从2005年到2010年，他曾担任Imclone Systems Incorporated公司（生命科学公司，专注于单克隆抗体，被礼来公司公司收购）的首席医疗官兼负责临床开发和监管事务的执行Vice President。在此之前，Rowinsky博士在癌症治疗和研究中心的药物开发研究所担任几个职位，包括研究所主任和SBC Endowed Chair for Early Drug Development。此前，他曾担任the University of Texas Health Science Center at San Antonio的医学肿瘤学部门的医学临床教授，以及Johns Hopkins University School of Medicine的肿瘤学副教授。自2011年以来，Rowinsky博士一直担任Biogen Idec，Inc.、Kitov Pharmaceuticals，Inc.和Fortress Biosciences，Inc.的董事会成员，并曾在BIND Therapeutics被辉瑞和NavideaBiopharmaceuticals，Inc.收购之前担任其董事会成员。Rowinsky博士在纽约大学（New York University）获得文科学士学位，并在范德堡大学（Vanderbilt University）获得医学博士学位。
Eric Rowinsky, is a Class I director who has served as a member of our Board of Directors since May 2017. Dr. Rowinsky has been the Executive Director and President of RGenix, Inc. since June 2016. He has also been a consulting Chief Medical Officer for Hummingbird Biosciences since February 2020 and served as the Chief Scientific Officer of Clearpath Development Co. from June 2016 to December 2020. Prior to this, Dr. Rowinsky served as the Head of Research and Development, Chief Medical Officer and Executive Vice President of Stemline Therapeutics, Inc. from February 2011 to January 2016. In 2010 Dr. Rowinsky co-founded Primrose Therapeutics and became its Chief Executive Officer, until it was acquired in 2011. From 2005 to 2010 he served as the Chief Medical Officer and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company focused on monoclonal antibodies, which was acquired by Eli Lilly and Company. Previous to that, Dr. Rowinsky held several positions at the Cancer Therapy and Research Center's Institute of Drug Development, including Director of the Institute and SBC Endowed Chair for Early Drug Development. Prior to that, he served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio and as Associate Professor of Oncology at the Johns Hopkins University School of Medicine. Since 2011 Dr. Rowinsky serves on the boards of directors of Biogen Idec, Inc., Purple Biotech, Inc, and Fortress Biosciences, Inc., and formerly served on the board of directors of BIND Therapeutics, prior to its acquisition by Pfizer, and Navidea Biopharmaceuticals, Inc. Dr. Rowinsky received a B.A. degree in Liberal Arts from New York University and earned his M.D. from Vanderbilt University. - Eric Rowinsky是一级董事，自2017年5月以来一直担任我们的董事会成员。Rowinsky博士自2016年6月起担任Rgenix，Inc.的执行董事兼总裁。他还自2016年6月起担任ClearPath Development Co.的首席科学官。在此之前，罗温斯基博士于2011年2月至2016年1月担任StemlineTherapeutics，Inc.研究与开发主管，首席医疗官兼执行Vice President。2010年，Rowinsky博士共同创立Primrose Therapeutics，并成为其首席执行官，直到2011年被收购。从2005年到2010年，他曾担任Imclone Systems Incorporated公司（生命科学公司，专注于单克隆抗体，被礼来公司公司收购）的首席医疗官兼负责临床开发和监管事务的执行Vice President。在此之前，Rowinsky博士在癌症治疗和研究中心的药物开发研究所担任几个职位，包括研究所主任和SBC Endowed Chair for Early Drug Development。此前，他曾担任the University of Texas Health Science Center at San Antonio的医学肿瘤学部门的医学临床教授，以及Johns Hopkins University School of Medicine的肿瘤学副教授。自2011年以来，Rowinsky博士一直担任Biogen Idec，Inc.、Kitov Pharmaceuticals，Inc.和Fortress Biosciences，Inc.的董事会成员，并曾在BIND Therapeutics被辉瑞和NavideaBiopharmaceuticals，Inc.收购之前担任其董事会成员。Rowinsky博士在纽约大学（New York University）获得文科学士学位，并在范德堡大学（Vanderbilt University）获得医学博士学位。
- Eric Rowinsky, is a Class I director who has served as a member of our Board of Directors since May 2017. Dr. Rowinsky has been the Executive Director and President of RGenix, Inc. since June 2016. He has also been a consulting Chief Medical Officer for Hummingbird Biosciences since February 2020 and served as the Chief Scientific Officer of Clearpath Development Co. from June 2016 to December 2020. Prior to this, Dr. Rowinsky served as the Head of Research and Development, Chief Medical Officer and Executive Vice President of Stemline Therapeutics, Inc. from February 2011 to January 2016. In 2010 Dr. Rowinsky co-founded Primrose Therapeutics and became its Chief Executive Officer, until it was acquired in 2011. From 2005 to 2010 he served as the Chief Medical Officer and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company focused on monoclonal antibodies, which was acquired by Eli Lilly and Company. Previous to that, Dr. Rowinsky held several positions at the Cancer Therapy and Research Center's Institute of Drug Development, including Director of the Institute and SBC Endowed Chair for Early Drug Development. Prior to that, he served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio and as Associate Professor of Oncology at the Johns Hopkins University School of Medicine. Since 2011 Dr. Rowinsky serves on the boards of directors of Biogen Idec, Inc., Purple Biotech, Inc, and Fortress Biosciences, Inc., and formerly served on the board of directors of BIND Therapeutics, prior to its acquisition by Pfizer, and Navidea Biopharmaceuticals, Inc. Dr. Rowinsky received a B.A. degree in Liberal Arts from New York University and earned his M.D. from Vanderbilt University.
- Paul Bunn
-
Paul Bunn，他是III类董事，自2021年6月起担任我们的董事会成员。Bunn博士自1984年以来一直担任科罗拉多大学医学院的医学教授。自2013年以来，Bunn博士一直担任科罗拉多大学医学院的杰出医学教授，自2006年以来，他一直担任科罗拉多大学医学院医学肿瘤科癌症研究James Dudley主席。Bunn博士曾于1987年至2009年担任科罗拉多大学癌症中心主任，并于1984年至1994年担任医学肿瘤科主任。Bunn博士是美国临床肿瘤学会ASCO的主席，也是其董事会成员。Bunn博士曾担任国际肺癌研究协会的首席执行官，总裁和董事会成员。Bunn博士也是美国癌症研究所协会的主席，并曾担任美国食品和药物管理局肿瘤药物咨询委员会的主席。Bunn博士在Amherst学院获得生物学学士学位，在Weill Cornell医学院获得医学博士学位。
Paul Bunn, is a Class III director who has served as a member of our Board of Directors since June 2021. Dr. Bunn has served as professor of Medicine at the University of Colorado School of Medicine since 1984 in progressive positions. Dr. Bunn has served as distinguished professor of Medicine since 2013 and the James Dudley Chair in Cancer Research, Division of Medical Oncology since 2006 at the University of Colorado School of Medicine. Dr. Bunn has served as the Director of the University of Colorado Cancer Center from 1987 to 2009 and the Head of the Division of Medical Oncology from 1984 to 1994. Dr. Bunn was the President of American Society of Clinical Oncology ASCO and a member of its board of directors. Dr. Bunn has served as Chief Executive Officer, President, and member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC). Dr. Bunn was also the President of the American Association of Cancer Institutes (AACI) and has chaired the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee. Dr. Bunn has received a B.A. degree in biology from Amherst College and earned his M.D. degree from Weill Cornell Medical College. - Paul Bunn，他是III类董事，自2021年6月起担任我们的董事会成员。Bunn博士自1984年以来一直担任科罗拉多大学医学院的医学教授。自2013年以来，Bunn博士一直担任科罗拉多大学医学院的杰出医学教授，自2006年以来，他一直担任科罗拉多大学医学院医学肿瘤科癌症研究James Dudley主席。Bunn博士曾于1987年至2009年担任科罗拉多大学癌症中心主任，并于1984年至1994年担任医学肿瘤科主任。Bunn博士是美国临床肿瘤学会ASCO的主席，也是其董事会成员。Bunn博士曾担任国际肺癌研究协会的首席执行官，总裁和董事会成员。Bunn博士也是美国癌症研究所协会的主席，并曾担任美国食品和药物管理局肿瘤药物咨询委员会的主席。Bunn博士在Amherst学院获得生物学学士学位，在Weill Cornell医学院获得医学博士学位。
- Paul Bunn, is a Class III director who has served as a member of our Board of Directors since June 2021. Dr. Bunn has served as professor of Medicine at the University of Colorado School of Medicine since 1984 in progressive positions. Dr. Bunn has served as distinguished professor of Medicine since 2013 and the James Dudley Chair in Cancer Research, Division of Medical Oncology since 2006 at the University of Colorado School of Medicine. Dr. Bunn has served as the Director of the University of Colorado Cancer Center from 1987 to 2009 and the Head of the Division of Medical Oncology from 1984 to 1994. Dr. Bunn was the President of American Society of Clinical Oncology ASCO and a member of its board of directors. Dr. Bunn has served as Chief Executive Officer, President, and member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC). Dr. Bunn was also the President of the American Association of Cancer Institutes (AACI) and has chaired the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee. Dr. Bunn has received a B.A. degree in biology from Amherst College and earned his M.D. degree from Weill Cornell Medical College.
- John Johnson
-
暂无中文简介
John Johnson, is a Class I director who has served as a member of our Board of Directors since April 2020. Effective March 16 2022 Mr. Johnson was appointed as chief executive officer and Board Director of Reaction Biology, a privately held company. Mr. Johnson was the Chief Executive Officer of Strongbridge Biopharma plc, a publicly traded biopharmaceutical company, from July 2020 until the company was acquired by Xeris Biopharma Holdings, Inc. in October 2021 and he currently sits on the Board of Directors of Xeris Biopharma Holdings, Inc. Mr. Johnson was a member of Strongbridge Biopharma Plc's board of directors from March 2015 until October 2021. Mr. Johnson recently served as a board member of Melinta Pharmaceuticals, Inc. through September 2019 having served as Chief Executive Officer from February 2019 through August 2019 and as interim Chief Executive Officer from October 2018 through February 2019. From January 2012 until August 2014 Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012 he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011 Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008 and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007 Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005 and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. Mr. Johnson currently serves on the Board of Directors of publicly traded companies Axogen Inc, and Autolus Therapeutics plc. Mr. Johnson is the former Chairman of Tranzyme Pharma, Inc., former lead independent director of Sucampo Pharmaceuticals, Inc. and a former director of Histogenics Corporation, AVEO Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and the Health Section Governing Board of Biotechnology Industry Organization. Mr. Johnson holds a B.S. from the East Stroudsburg University of Pennsylvania. -
暂无中文简介
- John Johnson, is a Class I director who has served as a member of our Board of Directors since April 2020. Effective March 16 2022 Mr. Johnson was appointed as chief executive officer and Board Director of Reaction Biology, a privately held company. Mr. Johnson was the Chief Executive Officer of Strongbridge Biopharma plc, a publicly traded biopharmaceutical company, from July 2020 until the company was acquired by Xeris Biopharma Holdings, Inc. in October 2021 and he currently sits on the Board of Directors of Xeris Biopharma Holdings, Inc. Mr. Johnson was a member of Strongbridge Biopharma Plc's board of directors from March 2015 until October 2021. Mr. Johnson recently served as a board member of Melinta Pharmaceuticals, Inc. through September 2019 having served as Chief Executive Officer from February 2019 through August 2019 and as interim Chief Executive Officer from October 2018 through February 2019. From January 2012 until August 2014 Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012 he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011 Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008 and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007 Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005 and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. Mr. Johnson currently serves on the Board of Directors of publicly traded companies Axogen Inc, and Autolus Therapeutics plc. Mr. Johnson is the former Chairman of Tranzyme Pharma, Inc., former lead independent director of Sucampo Pharmaceuticals, Inc. and a former director of Histogenics Corporation, AVEO Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and the Health Section Governing Board of Biotechnology Industry Organization. Mr. Johnson holds a B.S. from the East Stroudsburg University of Pennsylvania.
- Michelle Robertson
-
Michelle Robertson，他是III类董事，自2021年11月起担任我们的董事会成员。Robertson女士自2020年1月起担任上市公司Editas Medicine，Inc的首席财务官。Robertson女士曾于2018年10月至2020年1月担任上市生物技术公司首席财务官 Momenta的副总裁，并于2017年5月至2018年10月担任Momenta的财务规划和分析。2015年至2016年，罗伯逊女士担任生物制药公司Baxalta，Inc.（从Baxter International分拆出来）的肿瘤财务副总裁。从2012年到2015年，罗伯逊女士在Ironwood Pharmaceuticals, Inc.担任财务规划和分析以及卓越运营主管，在此之前，她在生物技术公司健赞公司（现为赛诺菲健赞）的肿瘤学和生物外科部门担任过各种财务和商业运营领导职务。罗伯逊女士在宾利大学获得金融学学士学位。
Michelle Robertson, is a Class III director who has served as a member of our Board of Directors since November 2021. Ms. Robertson has served as Chief Financial Officer of Editas Medicine, Inc, a publicly traded company, since January 2020. Ms. Robertson previously served as the Chief Financial Officer of Momenta Pharmaceuticals, Inc. "Momenta", a publicly traded biotechnology company, from October 2018 until January 2020 and as Vice President, Financial Planning and Analysis of Momenta from May 2017 to October 2018. From 2015 to 2016 Ms. Robertson was Vice President, Oncology Finance for Baxalta, Inc., a biopharmaceutical company, following its spin-off from Baxter International. From 2012 to 2015 Ms. Robertson served as Head of Financial Planning and Analysis and Operations Excellence at Ironwood Pharmaceuticals, Inc., and prior to that, held various Finance and Commercial Operations-leadership positions in the Oncology and Biosurgery divisions at Genzyme Corporation (now Sanofi Genzyme), a biotechnology company. Ms. Robertson received her B.S. in Finance from Bentley University. - Michelle Robertson，他是III类董事，自2021年11月起担任我们的董事会成员。Robertson女士自2020年1月起担任上市公司Editas Medicine，Inc的首席财务官。Robertson女士曾于2018年10月至2020年1月担任上市生物技术公司首席财务官 Momenta的副总裁，并于2017年5月至2018年10月担任Momenta的财务规划和分析。2015年至2016年，罗伯逊女士担任生物制药公司Baxalta，Inc.（从Baxter International分拆出来）的肿瘤财务副总裁。从2012年到2015年，罗伯逊女士在Ironwood Pharmaceuticals, Inc.担任财务规划和分析以及卓越运营主管，在此之前，她在生物技术公司健赞公司（现为赛诺菲健赞）的肿瘤学和生物外科部门担任过各种财务和商业运营领导职务。罗伯逊女士在宾利大学获得金融学学士学位。
- Michelle Robertson, is a Class III director who has served as a member of our Board of Directors since November 2021. Ms. Robertson has served as Chief Financial Officer of Editas Medicine, Inc, a publicly traded company, since January 2020. Ms. Robertson previously served as the Chief Financial Officer of Momenta Pharmaceuticals, Inc. "Momenta", a publicly traded biotechnology company, from October 2018 until January 2020 and as Vice President, Financial Planning and Analysis of Momenta from May 2017 to October 2018. From 2015 to 2016 Ms. Robertson was Vice President, Oncology Finance for Baxalta, Inc., a biopharmaceutical company, following its spin-off from Baxter International. From 2012 to 2015 Ms. Robertson served as Head of Financial Planning and Analysis and Operations Excellence at Ironwood Pharmaceuticals, Inc., and prior to that, held various Finance and Commercial Operations-leadership positions in the Oncology and Biosurgery divisions at Genzyme Corporation (now Sanofi Genzyme), a biotechnology company. Ms. Robertson received her B.S. in Finance from Bentley University.
- Lesley Solomon
-
Lesley Solomon，他是一名III类董事，已被重新分类为II类董事，自2022年3月31日起生效，自2021年6月起担任董事会成员。Solomon女士自2021年7月起担任ReDesign Health的风险主席。在此之前，Solomon女士于2017年7月至2021年6月担任Dana-Farber癌症研究所的首席创新官。2009年11月至2017年6月，所罗门女士在布莱根妇女医院担任布莱根创新中心的创始执行董事（2013年至2017年），2012年至2017年担任布莱根研究所的创新和战略总监，2009年至2012年担任布莱根研究所的电子慈善主任。Solomon女士也是Food Allergy Science Initiative FASI的联合创始人和董事会成员（2016年以来），并自2021年12月以来在私人控股公司Anomoly的董事会任职。所罗门女士在康奈尔大学获得英语学士学位，在哈佛商学院获得工商管理硕士学位。
Lesley Solomon, is a Class III Director who has been reclassified to a Class II Director effective March 31 2022 who has served as a member of the Board of Directors since June 2021. Ms. Solomon has served as Venture Chair of Redesign Health since July 2021. Prior to this, Ms. Solomon served as Chief Innovation Officer at Dana-Farber Cancer Institute from July 2017 to June 2021. From November 2009 to June 2017 Ms. Solomon served at Brigham and Women's Hospital as founding Executive Director of Brigham Innovation Hub from 2013 to 2017 Director, Innovation and Strategy, at Brigham Research Institute from 2012 to 2017 and Director, E-Philanthropy, at Brigham Research Institute from 2009 to 2012. Ms. Solomon is also the co-founder and board member of Food Allergy Science Initiative FASI since 2016 and serves on the board of directors of privately held company, Anomoly, since December 2021. Ms. Solomon received her B.A. in English from Cornell University and her M.B.A. from Harvard Business School. - Lesley Solomon，他是一名III类董事，已被重新分类为II类董事，自2022年3月31日起生效，自2021年6月起担任董事会成员。Solomon女士自2021年7月起担任ReDesign Health的风险主席。在此之前，Solomon女士于2017年7月至2021年6月担任Dana-Farber癌症研究所的首席创新官。2009年11月至2017年6月，所罗门女士在布莱根妇女医院担任布莱根创新中心的创始执行董事（2013年至2017年），2012年至2017年担任布莱根研究所的创新和战略总监，2009年至2012年担任布莱根研究所的电子慈善主任。Solomon女士也是Food Allergy Science Initiative FASI的联合创始人和董事会成员（2016年以来），并自2021年12月以来在私人控股公司Anomoly的董事会任职。所罗门女士在康奈尔大学获得英语学士学位，在哈佛商学院获得工商管理硕士学位。
- Lesley Solomon, is a Class III Director who has been reclassified to a Class II Director effective March 31 2022 who has served as a member of the Board of Directors since June 2021. Ms. Solomon has served as Venture Chair of Redesign Health since July 2021. Prior to this, Ms. Solomon served as Chief Innovation Officer at Dana-Farber Cancer Institute from July 2017 to June 2021. From November 2009 to June 2017 Ms. Solomon served at Brigham and Women's Hospital as founding Executive Director of Brigham Innovation Hub from 2013 to 2017 Director, Innovation and Strategy, at Brigham Research Institute from 2012 to 2017 and Director, E-Philanthropy, at Brigham Research Institute from 2009 to 2012. Ms. Solomon is also the co-founder and board member of Food Allergy Science Initiative FASI since 2016 and serves on the board of directors of privately held company, Anomoly, since December 2021. Ms. Solomon received her B.A. in English from Cornell University and her M.B.A. from Harvard Business School.
- John H. Johnson
-
John H. Johnson，他曾一直担任Xeris Pharmaceuticals, Inc.董事（2013年11月以来）。他曾担任Dendreon Corporation的总裁和首席执行官（从2012年1月到2014年8月）。他此前曾担任Savient Pharmaceuticals公司（一家制药公司）的首席执行官兼董事（从2011年1月到2012年1月）。此前，他曾担任Eli Lilly and Company的肿瘤学单位的高级副总裁兼总裁（从2009年11月到2011年1月）。他也曾担任ImClone Systems Incorporated公司的首席执行官（从2007年到2009年11月），也曾任职于ImClone公司的董事会（直到2008年被Eli Lilly公司收购）。加入ImClone公司之前，他曾担任Johnson & Johnson公司的全球生物制药单位的公司集团主席（从2005年到2007年）、Ortho Biotech Products LP 和Ortho Biotech Canada单位的总裁（从2003年到2005年）、 CNS, Pharmaceuticals Group战略单位的全球副总裁（从2001年到2003年）。他目前担任Tranzyme公司和Dendreon Corporation的董事会主席，以及Cempra公司（一个制药公司临床阶段）的董事。他也担任the Pharmaceutical Research and Manufacturers of America的董事会成员，以及the Health Section Governing Board of Biotechnology Industry Organization的成员。他持有the East Stroudsburg University of Pennsylvania的学士学位。
John H. Johnson has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Mr. Johnson served on the board of directors of Strongbridge since March 2015 and as the Chief Executive Officer of Strongbridge from July 2020 to October 2021. Since March 2022 Mr. Johnson has served as Chief Executive Officer and Director of Reaction Biology Corp., a biotechnology company. Mr. Johnson recently served as a board member of Melinta Pharmaceuticals, Inc. through September 2019 having served as Chief Executive Officer from February 2019 through August 2019 and as interim Chief Executive Officer from October 2018 through February 2019. Mr. Johnson is also a member of the board of directors of Verastem, Inc. also known as Verastem Oncology and Autolus Therapeutics. From January 2012 until August 2014 Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012 he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011 Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008 and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007 Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005 and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. Mr.Johnson is the former Chairman of Tranzyme Pharma, Inc., former lead independent director of Sucampo Pharmaceuticals, Inc. and a former director of Histogenics Corporation, AVEO Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and the Health Section Governing Board of Biotechnology Industry Organization. - John H. Johnson，他曾一直担任Xeris Pharmaceuticals, Inc.董事（2013年11月以来）。他曾担任Dendreon Corporation的总裁和首席执行官（从2012年1月到2014年8月）。他此前曾担任Savient Pharmaceuticals公司（一家制药公司）的首席执行官兼董事（从2011年1月到2012年1月）。此前，他曾担任Eli Lilly and Company的肿瘤学单位的高级副总裁兼总裁（从2009年11月到2011年1月）。他也曾担任ImClone Systems Incorporated公司的首席执行官（从2007年到2009年11月），也曾任职于ImClone公司的董事会（直到2008年被Eli Lilly公司收购）。加入ImClone公司之前，他曾担任Johnson & Johnson公司的全球生物制药单位的公司集团主席（从2005年到2007年）、Ortho Biotech Products LP 和Ortho Biotech Canada单位的总裁（从2003年到2005年）、 CNS, Pharmaceuticals Group战略单位的全球副总裁（从2001年到2003年）。他目前担任Tranzyme公司和Dendreon Corporation的董事会主席，以及Cempra公司（一个制药公司临床阶段）的董事。他也担任the Pharmaceutical Research and Manufacturers of America的董事会成员，以及the Health Section Governing Board of Biotechnology Industry Organization的成员。他持有the East Stroudsburg University of Pennsylvania的学士学位。
- John H. Johnson has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Mr. Johnson served on the board of directors of Strongbridge since March 2015 and as the Chief Executive Officer of Strongbridge from July 2020 to October 2021. Since March 2022 Mr. Johnson has served as Chief Executive Officer and Director of Reaction Biology Corp., a biotechnology company. Mr. Johnson recently served as a board member of Melinta Pharmaceuticals, Inc. through September 2019 having served as Chief Executive Officer from February 2019 through August 2019 and as interim Chief Executive Officer from October 2018 through February 2019. Mr. Johnson is also a member of the board of directors of Verastem, Inc. also known as Verastem Oncology and Autolus Therapeutics. From January 2012 until August 2014 Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012 he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011 Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008 and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007 Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005 and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. Mr.Johnson is the former Chairman of Tranzyme Pharma, Inc., former lead independent director of Sucampo Pharmaceuticals, Inc. and a former director of Histogenics Corporation, AVEO Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and the Health Section Governing Board of Biotechnology Industry Organization.
- Michael G. Kauffman
-
Michael G. Kauffman，从2011年开始担任Karyopharm公司（Karyopharm）的首席执行官，从2008年开始一直担任公司董事。 2008年，他和Dr. Sharon 共同创立Karyopharm公司（Karyopharm），从2011年1月到2013年12月，他担任公司总裁，从2012年12月到2013年12月，他担任首席医务官。在加入Karyopharm公司（Karyopharm）之前，从2009年11月到2010年12月，他是Onyx 制药公司（Onyx Pharmaceuticals Inc.）的首席医务官，这是一家生物制药公司，曾在2009年11月收购Proteolix 公司（Proteolix Inc.），这是他从2008年11月开始担任首席医务官的公司，在那里他曾推动了Kyprolis carfilzomib 的发展，这是2012年7月得到FDA的批准的难治性多发性骨髓瘤的新型蛋白酶体抑制剂。在加入Onyx 制药公司（Onyx Pharmaceuticals Inc.）之前，从2006年到2008年，他是Bessemer 创投合伙企业的运营合伙人，在那里他领导过向生物科技公司的投资行为。在那之前，从2006年到2008年，他是Epix制药公司（Epix Pharmaceuticals, Inc.）的总裁和首席执行官，这是一家2009年在马萨诸塞州法律下通过对债权人的分配实行清算程序的生物制药公司；从2002年开始，他担任Predix制药公司（Predix Pharmaceuticals, Inc.）的总裁和首席执行官，这是一家研究G蛋白偶联型受体（GPCR）的私人生物制药公司，一直到该公司2006年被Epix制药公司（Epix Pharmaceuticals, Inc.）并购，在那里他领导了被与Epix制药公司（Epix Pharmaceuticals, Inc.）的合并，监督四个新的临床候选人的发现和开发，并领导安进公司（Amgen）和葛兰素史克公司（GlaxoSmithKline）的合作交易。From March 2000 to September 2002 Dr. Kauffman was Vice President, Clinical at Pharmaceuticals, Inc., a biopharmaceutical company, where he led the Velcade development program。 从2000年3月到2002年9月，他是Millennium 制药公司（Pharmaceuticals, Inc.）临床副总裁，这是一家生物制药公司，在那里他领导了Velcade 发展计划。从1997年9月到2000年3月，他在Millennium预测医学公司（Millennium Predictive Medicine, Inc.）担任多个高级职务，这是一家生物制药公司，是Millennium 制药公司（Pharmaceuticals, Inc.）的子公司，在那里他领导了主要癌症，包括恶性黑色素瘤新的分子诊断的发明和发展，也领导了和贝克顿 - 迪金森（Becton-Dickenson）和施贵宝公司（Bristol Myers Squibb）的交易。从1995年8月到1997年9月，他在Biogen Idec公司（Biogen Idec, Inc.）担任多个高级职务，这是一家生物制药公司，在那里他领导了抗CD40L抗体在自身免疫性疾病和炎症性疾病的临床发展，也是Biogen Idec公司（Biogen Idec, Inc.）业务发展团队的主要医务顾问。目前，他是Verastem公司（Verastem Inc.）的董事和薪酬委员会委员，这是一家生物制药公司，是Zalicus公司（Zalicus Inc.）（原CombinatoRx公司）董事和审计委员会与薪酬委员会委员，这是一家上市的生物制药公司，也是 Metamark 遗传学公司（Metamark Genetics Inc.）的董事和薪酬委员会委员，这是一家私人的分子诊断公司。他在阿默斯特学院（Amherst College）获得生物化学学士，在约翰霍普金斯大学医学院（Johns Hopkins Medical School ）获得医学博士和哲学博士，在在贝斯以色列医院（Beth Israel）（现在的贝斯以色列Deaconness医疗中心）和马萨诸塞州总医院（Massachusetts General Hospital）的内科，风湿科实习。他在内科方面得到委员会认证。
Michael G. Kauffman, is a Class I director who has served as a member of our Board of Directors since November 2012 and our lead director since June 2016. Dr. Kauffman was the cofounding Chief Executive Officer of Karyopharm Therapeutics Inc., a publicly traded commercial stage biotechnology company, from January 2011 to April 2021 and is currently Senior Clinical Advisor and member of the Board of Directors of the Company. Prior to this, Dr. Kauffman was Science Advisor to Bessemer Venture Partners from 2008 to 2011. Dr. Kauffman was the Chief Medical Officer of Onyx Pharmaceuticals, Inc., a publicly traded biotechnology company, from November 2009 until December 2010. Dr. Kauffman was the Chief Medical Officer of Proteolix, Inc., a privately held pharmaceutical company, from April 2009 until November 2009 when it was acquired by Onyx Pharmaceuticals, Inc. From September 2002 until July 2008 Dr. Kauffman was the President and Chief Executive Officer of EPIX Pharmaceuticals, Inc., a publicly traded biotechnology company that underwent liquidation proceedings in 2009. Dr. Kauffman joined Predix Pharmaceuticals, Inc., the predecessor to EPIX, in September 2002 as President and Chief Executive Officer. From 1997 to 2002 he held a number of senior medical and program leadership positions at Millennium Pharmaceuticals, Inc., then a publicly traded biotechnology company, including Vice President, Medicine and VELCADE Program Leader as well as co-founder and Vice President of Medicine at Millennium Predictive Medicine, a wholly-owned subsidiary of Millennium. Dr. Kauffman also served as Medical Director at Biogen Corporation now Biogen, Inc., a publicly traded biotechnology company. Dr. Kauffman has served on the board of directors of Karyopharm Therapeutics, Inc. since January 2011. He also currently serves on the board of directors of Kezar Biosciences, Adicet Bio, Inc., and BioVictriX Therapeutics Plc. He previously served on the boards of directors of Zalicus, Inc, EPIX and Predix and on the board of Proteolix prior to becoming the company's chief medical officer. Dr. Kauffman received an M.D. and Ph.D. in molecular biology and biochemistry from Johns Hopkins University and holds a B.A. in biochemistry from Amherst College. Dr. Kauffman trained in Internal Medicine at Beth Israel Deaconess and Massachusetts General Hospitals, and is board certified in internal medicine. - Michael G. Kauffman，从2011年开始担任Karyopharm公司（Karyopharm）的首席执行官，从2008年开始一直担任公司董事。 2008年，他和Dr. Sharon 共同创立Karyopharm公司（Karyopharm），从2011年1月到2013年12月，他担任公司总裁，从2012年12月到2013年12月，他担任首席医务官。在加入Karyopharm公司（Karyopharm）之前，从2009年11月到2010年12月，他是Onyx 制药公司（Onyx Pharmaceuticals Inc.）的首席医务官，这是一家生物制药公司，曾在2009年11月收购Proteolix 公司（Proteolix Inc.），这是他从2008年11月开始担任首席医务官的公司，在那里他曾推动了Kyprolis carfilzomib 的发展，这是2012年7月得到FDA的批准的难治性多发性骨髓瘤的新型蛋白酶体抑制剂。在加入Onyx 制药公司（Onyx Pharmaceuticals Inc.）之前，从2006年到2008年，他是Bessemer 创投合伙企业的运营合伙人，在那里他领导过向生物科技公司的投资行为。在那之前，从2006年到2008年，他是Epix制药公司（Epix Pharmaceuticals, Inc.）的总裁和首席执行官，这是一家2009年在马萨诸塞州法律下通过对债权人的分配实行清算程序的生物制药公司；从2002年开始，他担任Predix制药公司（Predix Pharmaceuticals, Inc.）的总裁和首席执行官，这是一家研究G蛋白偶联型受体（GPCR）的私人生物制药公司，一直到该公司2006年被Epix制药公司（Epix Pharmaceuticals, Inc.）并购，在那里他领导了被与Epix制药公司（Epix Pharmaceuticals, Inc.）的合并，监督四个新的临床候选人的发现和开发，并领导安进公司（Amgen）和葛兰素史克公司（GlaxoSmithKline）的合作交易。From March 2000 to September 2002 Dr. Kauffman was Vice President, Clinical at Pharmaceuticals, Inc., a biopharmaceutical company, where he led the Velcade development program。 从2000年3月到2002年9月，他是Millennium 制药公司（Pharmaceuticals, Inc.）临床副总裁，这是一家生物制药公司，在那里他领导了Velcade 发展计划。从1997年9月到2000年3月，他在Millennium预测医学公司（Millennium Predictive Medicine, Inc.）担任多个高级职务，这是一家生物制药公司，是Millennium 制药公司（Pharmaceuticals, Inc.）的子公司，在那里他领导了主要癌症，包括恶性黑色素瘤新的分子诊断的发明和发展，也领导了和贝克顿 - 迪金森（Becton-Dickenson）和施贵宝公司（Bristol Myers Squibb）的交易。从1995年8月到1997年9月，他在Biogen Idec公司（Biogen Idec, Inc.）担任多个高级职务，这是一家生物制药公司，在那里他领导了抗CD40L抗体在自身免疫性疾病和炎症性疾病的临床发展，也是Biogen Idec公司（Biogen Idec, Inc.）业务发展团队的主要医务顾问。目前，他是Verastem公司（Verastem Inc.）的董事和薪酬委员会委员，这是一家生物制药公司，是Zalicus公司（Zalicus Inc.）（原CombinatoRx公司）董事和审计委员会与薪酬委员会委员，这是一家上市的生物制药公司，也是 Metamark 遗传学公司（Metamark Genetics Inc.）的董事和薪酬委员会委员，这是一家私人的分子诊断公司。他在阿默斯特学院（Amherst College）获得生物化学学士，在约翰霍普金斯大学医学院（Johns Hopkins Medical School ）获得医学博士和哲学博士，在在贝斯以色列医院（Beth Israel）（现在的贝斯以色列Deaconness医疗中心）和马萨诸塞州总医院（Massachusetts General Hospital）的内科，风湿科实习。他在内科方面得到委员会认证。
- Michael G. Kauffman, is a Class I director who has served as a member of our Board of Directors since November 2012 and our lead director since June 2016. Dr. Kauffman was the cofounding Chief Executive Officer of Karyopharm Therapeutics Inc., a publicly traded commercial stage biotechnology company, from January 2011 to April 2021 and is currently Senior Clinical Advisor and member of the Board of Directors of the Company. Prior to this, Dr. Kauffman was Science Advisor to Bessemer Venture Partners from 2008 to 2011. Dr. Kauffman was the Chief Medical Officer of Onyx Pharmaceuticals, Inc., a publicly traded biotechnology company, from November 2009 until December 2010. Dr. Kauffman was the Chief Medical Officer of Proteolix, Inc., a privately held pharmaceutical company, from April 2009 until November 2009 when it was acquired by Onyx Pharmaceuticals, Inc. From September 2002 until July 2008 Dr. Kauffman was the President and Chief Executive Officer of EPIX Pharmaceuticals, Inc., a publicly traded biotechnology company that underwent liquidation proceedings in 2009. Dr. Kauffman joined Predix Pharmaceuticals, Inc., the predecessor to EPIX, in September 2002 as President and Chief Executive Officer. From 1997 to 2002 he held a number of senior medical and program leadership positions at Millennium Pharmaceuticals, Inc., then a publicly traded biotechnology company, including Vice President, Medicine and VELCADE Program Leader as well as co-founder and Vice President of Medicine at Millennium Predictive Medicine, a wholly-owned subsidiary of Millennium. Dr. Kauffman also served as Medical Director at Biogen Corporation now Biogen, Inc., a publicly traded biotechnology company. Dr. Kauffman has served on the board of directors of Karyopharm Therapeutics, Inc. since January 2011. He also currently serves on the board of directors of Kezar Biosciences, Adicet Bio, Inc., and BioVictriX Therapeutics Plc. He previously served on the boards of directors of Zalicus, Inc, EPIX and Predix and on the board of Proteolix prior to becoming the company's chief medical officer. Dr. Kauffman received an M.D. and Ph.D. in molecular biology and biochemistry from Johns Hopkins University and holds a B.A. in biochemistry from Amherst College. Dr. Kauffman trained in Internal Medicine at Beth Israel Deaconess and Massachusetts General Hospitals, and is board certified in internal medicine.
- Timothy Barberich
-
Timothy Barberich， 他是二类董事，并担任董事（2014年3月以来）。他是Sepracor公司（上市的研究型的马萨诸塞州马尔伯勒的制药公司，2009年被Dainippon Sumitomo Pharma公司收购）的创始人、前任主席兼首席执行官。他于1984年创立Sepracor公司，并担任首席执行官（从1984年到2007年5月）和董事会主席（从1990年到2009年）。他一直担任BioNevia Pharmaceuticals的首席执行官兼主席（2008年6月以来）。他目前任职于HeartWare International公司（上市公司）和GI Dynamics公司（上市公司）的董事会，以及Tokai Pharmaceuticals公司（私人公司）和Neurovance公司（私人公司）的董事会。他也曾任职BioSphere Medical公司和GeminX Pharmaceuticals公司（两家公司于2010年被收购）的董事会。他也曾任职Boston Medical Center的监事会，以及the Pharmaceutical Research and Manufacturers'Association（PhRMA）的董事会。创立Sepracor公司之前，他曾任职Bedford公司和Millipore Corporation（位于马萨诸塞州）10年，担任高级执行官。他毕业于Kings College，持有化学科学学士学位。
Timothy Barberich, is a Class II director who has served as a member of our Board of Directors since March 2014. Mr. Barberich is founder and former Chairman and Chief Executive Officer of Sepracor Inc., a publicly traded, research-based, pharmaceutical company based in Marlborough, Massachusetts, which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009. He founded Sepracor in 1984 and served as Chief Executive Officer from 1984 to May 2007 and as Chairman of the Board from 1990 to 2009. He currently serves on the board of directors of publicly traded Frequency Therapeutics, Inc., and TScan Biotechnology Inc. He also previously served on the boards of directors of Neurovance Inc, Inotek Pharmaceuticals, Inc., HeartWare, International, Inc., Tokai Pharmaceuticals, BioSphere Medical, Inc. and GeminX Pharmaceuticals until each company was acquired. Mr. Barberich has also served on the board of trustees of Boston Medical Center and the board of the Pharmaceutical Research and Manufacturers' Association PhRMA. Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Bedford, Massachusetts-based Millipore Corporation. Mr. Barberich is a graduate of Kings College and holds a Bachelor's of Science degree in Chemistry. - Timothy Barberich， 他是二类董事，并担任董事（2014年3月以来）。他是Sepracor公司（上市的研究型的马萨诸塞州马尔伯勒的制药公司，2009年被Dainippon Sumitomo Pharma公司收购）的创始人、前任主席兼首席执行官。他于1984年创立Sepracor公司，并担任首席执行官（从1984年到2007年5月）和董事会主席（从1990年到2009年）。他一直担任BioNevia Pharmaceuticals的首席执行官兼主席（2008年6月以来）。他目前任职于HeartWare International公司（上市公司）和GI Dynamics公司（上市公司）的董事会，以及Tokai Pharmaceuticals公司（私人公司）和Neurovance公司（私人公司）的董事会。他也曾任职BioSphere Medical公司和GeminX Pharmaceuticals公司（两家公司于2010年被收购）的董事会。他也曾任职Boston Medical Center的监事会，以及the Pharmaceutical Research and Manufacturers'Association（PhRMA）的董事会。创立Sepracor公司之前，他曾任职Bedford公司和Millipore Corporation（位于马萨诸塞州）10年，担任高级执行官。他毕业于Kings College，持有化学科学学士学位。
- Timothy Barberich, is a Class II director who has served as a member of our Board of Directors since March 2014. Mr. Barberich is founder and former Chairman and Chief Executive Officer of Sepracor Inc., a publicly traded, research-based, pharmaceutical company based in Marlborough, Massachusetts, which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009. He founded Sepracor in 1984 and served as Chief Executive Officer from 1984 to May 2007 and as Chairman of the Board from 1990 to 2009. He currently serves on the board of directors of publicly traded Frequency Therapeutics, Inc., and TScan Biotechnology Inc. He also previously served on the boards of directors of Neurovance Inc, Inotek Pharmaceuticals, Inc., HeartWare, International, Inc., Tokai Pharmaceuticals, BioSphere Medical, Inc. and GeminX Pharmaceuticals until each company was acquired. Mr. Barberich has also served on the board of trustees of Boston Medical Center and the board of the Pharmaceutical Research and Manufacturers' Association PhRMA. Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Bedford, Massachusetts-based Millipore Corporation. Mr. Barberich is a graduate of Kings College and holds a Bachelor's of Science degree in Chemistry.
高管简历
中英对照 | 中文 | 英文- Brian Stuglik
Brian Stuglik是二类董事，自2019年7月起担任首席执行官，自2017年9月起担任董事会成员。Stuglik先生于2016年1月创立Proventus Health Solutions，在美国和国际药品开发，产品战略和商业化方面拥有超过三十年的经验。在创立Proventus Health Solutions之前，Stuglik先生于2009年至2015年12月担任礼来公司肿瘤部门的Vice President兼首席营销官。Stuglik先生在普渡大学（Purdue University）获得药学理学学士学位，并持有美国临床肿瘤学学会、美国癌症研究协会和国际肺癌研究协会的会员资格。
Brian Stuglik, is a Class II director who has served as our Chief Executive Officer since July 2019 and as a member of our Board of Directors since September 2017. Mr. Stuglik founded Proventus Health Solutions, a consulting company for pharmaceutical and biotechnology companies, in January 2016 and has over three decades of experience in U.S. and international pharmaceutical development, product strategy, and commercialization. Prior to founding Proventus Health Solutions, Mr. Stuglik served as the Vice President and Chief Marketing Officer for the oncology division of Eli Lilly and Company, from 2009 to December 2015. Mr. Stuglik currently serves on the board of directors of publicly traded Oncopeptides AB ONCO and Puma Biotechnology, Inc. (PBYI). Mr. Stuglik received a Bachelor of Science in Pharmacy from Purdue University and holds memberships in the American Society of Clinical Oncology, the American Association of Cancer Research, and the International Association for the Study of Lung Cancer.- Brian Stuglik是二类董事，自2019年7月起担任首席执行官，自2017年9月起担任董事会成员。Stuglik先生于2016年1月创立Proventus Health Solutions，在美国和国际药品开发，产品战略和商业化方面拥有超过三十年的经验。在创立Proventus Health Solutions之前，Stuglik先生于2009年至2015年12月担任礼来公司肿瘤部门的Vice President兼首席营销官。Stuglik先生在普渡大学（Purdue University）获得药学理学学士学位，并持有美国临床肿瘤学学会、美国癌症研究协会和国际肺癌研究协会的会员资格。
- Brian Stuglik, is a Class II director who has served as our Chief Executive Officer since July 2019 and as a member of our Board of Directors since September 2017. Mr. Stuglik founded Proventus Health Solutions, a consulting company for pharmaceutical and biotechnology companies, in January 2016 and has over three decades of experience in U.S. and international pharmaceutical development, product strategy, and commercialization. Prior to founding Proventus Health Solutions, Mr. Stuglik served as the Vice President and Chief Marketing Officer for the oncology division of Eli Lilly and Company, from 2009 to December 2015. Mr. Stuglik currently serves on the board of directors of publicly traded Oncopeptides AB ONCO and Puma Biotechnology, Inc. (PBYI). Mr. Stuglik received a Bachelor of Science in Pharmacy from Purdue University and holds memberships in the American Society of Clinical Oncology, the American Association of Cancer Research, and the International Association for the Study of Lung Cancer.
- Robert Gagnon
Robert Gagnon自2018年8月起担任我们的首席财务官。在加入我们之前，Gagnon先生于2013年11月至2018年8月担任HarvardBioscience，Inc.首席财务官。2012年至2013年，Gagnon先生担任清洁海港公司的执行Vice President、首席财务官和财务主管Gagnon先生先前的经验包括担任Biogen Idec，Inc.的首席会计官和财务总监，以及德勤会计师事务所（Deloitte&Touche，LLP）和普华永道会计师事务所（PricewaterhouseCoopers，LLP）的各种高级职位。
Robert Gagnon, joined Verastem as Chief Financial Officer in August 2018. Prior to joining us, Mr. Gagnon served as the Chief Financial Officer for Harvard Bioscience, Inc. from November 2013 to August 2018. From 2012 through 2013 Mr. Gagnon served as the Executive Vice President, Chief Financial Officer and Treasurer at Clean Harbors, Inc. Mr. Gagnon's prior experience includes serving as Chief Accounting Officer and Controller at Biogen Idec, Inc., as well as a variety of senior positions at Deloitte & Touche, LLP, and PriceWaterhouseCoopers, LLP. Mr. Gagnon holds an M.B.A. from the MIT Sloan School of Management and a Bachelor of Arts degree in accounting from Bentley College.- Robert Gagnon自2018年8月起担任我们的首席财务官。在加入我们之前，Gagnon先生于2013年11月至2018年8月担任HarvardBioscience，Inc.首席财务官。2012年至2013年，Gagnon先生担任清洁海港公司的执行Vice President、首席财务官和财务主管Gagnon先生先前的经验包括担任Biogen Idec，Inc.的首席会计官和财务总监，以及德勤会计师事务所（Deloitte&Touche，LLP）和普华永道会计师事务所（PricewaterhouseCoopers，LLP）的各种高级职位。
- Robert Gagnon, joined Verastem as Chief Financial Officer in August 2018. Prior to joining us, Mr. Gagnon served as the Chief Financial Officer for Harvard Bioscience, Inc. from November 2013 to August 2018. From 2012 through 2013 Mr. Gagnon served as the Executive Vice President, Chief Financial Officer and Treasurer at Clean Harbors, Inc. Mr. Gagnon's prior experience includes serving as Chief Accounting Officer and Controller at Biogen Idec, Inc., as well as a variety of senior positions at Deloitte & Touche, LLP, and PriceWaterhouseCoopers, LLP. Mr. Gagnon holds an M.B.A. from the MIT Sloan School of Management and a Bachelor of Arts degree in accounting from Bentley College.
- Daniel Paterson
Daniel Paterson，他曾一直担任我们的首席商务官（2013年7月以来）、我们的副总裁、公司发展和诊断主管（从2012年3月到2013年7月）。加入我们之前，他曾于2011年担任顾问（直到2012年加入我们）。从2009年到2010年，他曾担任On-Q-ity公司的首席运营官。他曾担任The DNA Repair Company的总裁兼首席执行官（从2006年到2009年被On-Q-ity公司收购）。此前，他曾担任IMS Health公司、CareTools公司、OnCare公司和Axion公司的高级职务。
Daniel Paterson, has served as our President since June 2019 in addition to serving as our Chief Operating Officer since December 2014 our Chief Business Officer from July 2013 to December 2014 and as our Vice President, Head of Corporate Development and Diagnostics from March 2012 until July 2013. Prior to joining us in March 2012 Mr. Paterson was a consultant in 2011. From 2009 through 2010 Mr. Paterson was the Chief Operating Officer of On-Q-ity. Mr. Paterson was the President and Chief Executive Officer of The DNA Repair Company from 2006 until 2009 when it was acquired by On-Q-ity. Previously, he held senior level positions at IMS Health, CareTools, OnCare, and Axion. Mr. Paterson holds a B.A. in Biology from Boston University, and attended the Northeastern University Graduate Pharmacology program.- Daniel Paterson，他曾一直担任我们的首席商务官（2013年7月以来）、我们的副总裁、公司发展和诊断主管（从2012年3月到2013年7月）。加入我们之前，他曾于2011年担任顾问（直到2012年加入我们）。从2009年到2010年，他曾担任On-Q-ity公司的首席运营官。他曾担任The DNA Repair Company的总裁兼首席执行官（从2006年到2009年被On-Q-ity公司收购）。此前，他曾担任IMS Health公司、CareTools公司、OnCare公司和Axion公司的高级职务。
- Daniel Paterson, has served as our President since June 2019 in addition to serving as our Chief Operating Officer since December 2014 our Chief Business Officer from July 2013 to December 2014 and as our Vice President, Head of Corporate Development and Diagnostics from March 2012 until July 2013. Prior to joining us in March 2012 Mr. Paterson was a consultant in 2011. From 2009 through 2010 Mr. Paterson was the Chief Operating Officer of On-Q-ity. Mr. Paterson was the President and Chief Executive Officer of The DNA Repair Company from 2006 until 2009 when it was acquired by On-Q-ity. Previously, he held senior level positions at IMS Health, CareTools, OnCare, and Axion. Mr. Paterson holds a B.A. in Biology from Boston University, and attended the Northeastern University Graduate Pharmacology program.